期刊文献+

顺铂和5-氟尿嘧啶/醛氢叶酸双周疗法治疗晚期乳腺癌临床研究 被引量:2

The clinical study of bimonthly 5-Fluorouracil (5-Fu)/Leucovorin (LV) combined with cisplatin (DDP) in treatment of advanced breast cancer
下载PDF
导出
摘要 目的观察顺铂(Cisplatin,DDP),5-氟尿嘧啶(5-Fluorouracil,5-Fu)/醛氢叶酸(Leucovorin,LV)双周疗法治疗晚期乳腺癌的疗效及其毒性。方法病理明确的36例晚期乳腺癌病人进入研究组,全组病人既往均行CMF/CAF方案化疗及常规放疗。治疗方法:LV200mg/m2,静脉输注2h,后接5-Fu  375mg/m2静推10min,再接5-Fu 3.0g/m2,用输液泵连续静脉输注48h,顺铂25mg/m2,d1-2,静脉滴注,以上治疗每两周一次,28天重复,所有病人至少接受2疗程的治疗。结果经过两周期的化疗,完全缓解(Complete remission,CR)2例(5.6%),部分缓解(prtial remission PR)18例(50%),10例病人稳定(27.7%),恶心、呕吐和骨髓抑制为主要不良反应,毒性相对较弱。结论顺铂和5-氟尿嘧啶/醛氢叶酸双周疗法治疗晚期乳腺癌缓解率高,毒性相对低。 ObjectiveTo evaluate the efficacy and to toxicity of DDP combined with himonthly 5-Fu in the patients with advanced breast cancer. MethodsThe patients with a histologic diagnosis of breast cancer were eligible. All patients were treated with CMF/CAF and conventional radiotherapy. The chemotherapy regimen was comprised of bimonthly 2-hour infusion of leucovorin 200mg/m2 followed by 10-minute intravenous bolus of 5-Fu 375mg/m2, then 48-hour infusion of 5-Fu 3.0g/m2using an ambulatory pump, Cisplatm 25mg/m2d1-2infusion. Every 28 days one cycles. All pationts were received at least two cycles of treatment. ResultsAfter two cycles of chemotherapy. 2 obtained complete remission (CR) (5.6%), 18 obtained partial remission (PR) (50%), 10 had stable disease (SD) (27.7%). Nausea vomiting and myelosuppression were mainly side effects. Toxicity was comparatively mild. ConclusionData from the current study indicated that bimonthly 5-Fu/LV combined with DDP had moderate activity but comparatively mild toxicity for advanced breast cancer.
作者 潘达超 谢忠
出处 《肿瘤防治研究》 CAS CSCD 2002年第1期69-70,共2页 Cancer Research on Prevention and Treatment
关键词 顺铂 5-氟尿嘧啶 醛氢叶酸 晚期乳腺癌 联合化疗 Cisplatin 5-Fluorouracil Leucovorin Advanced breast cancer Combination chemotherapy
  • 相关文献

参考文献1

二级参考文献8

  • 1PotierP.Thesynthesisofnavelbine,prototypeofanewseriesofvinblastinedervatives[J].SeminOncol,1989,16(2suppl4):2-4.
  • 2CrosS,TakooudjuM,Shaepelynck-Lataste.Comparativeinvitroandinvivostudyofnavelbineditartrate(Nor54anhydrovinblastine)withthetwoantitumorcompounds:Vinblastineandvinecristine.Proceedingofthe14thInternationalCongressofChemotherapy[J].RecentAdvChemother,1985,1(1):477-478.
  • 3BoreP,RahamaniR,VanCanfortJ,etal.Pharmacokineticsofanewanticancerdrugy,Navelbine,inpatitnets.Comparationstudyofradioimmunologyandradioactivedeterminationmetheds[J].CancerChemotherPharmacol,1989,23(4):247-251.
  • 4AbeloffMD.Vinorebine(Navelbine)inthetreatmentofbreastcancer:Asummary[J].SeminOncol,1995,22(suppl5):1-4.
  • 5AbeloffMD,ArmtageJO,LichterAS,etal.ClinicalOncology[M],NewYork,ChurchillLivingstoneInc,1995,1680.
  • 6LevineWN,BramwellVH,PritchardKI,etal.Randomizedtrailofintensivecyclophosphamide,epirubicin,andfluorouracilchemotherapycomparedwithcyclophosphamide,methotrexate,andfluorouracilinpremenopausalwomenwithnode-positivebreastcancer[J].JClinOncol,1998,16(8):2651-2658
  • 7JonesS,WinterE,VogelC,etal.Randomizedcomparationofvinorelbineandmelphalaninanthracycline-refractoryadvancedbreastcancer[J].JClinOncol,1995,13(8):2567-2574.
  • 8SpielmanM,DorvalT,TurpinF,etal.PhaseⅡtrialofvinorelbine/doxorubicinasfirst-linetherapyofadvancedbreastcancer[J].JClinOncol,1990,11(6):1764-1770.

共引文献12

同被引文献8

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部